The strong bleeding reduction data de-risks the VM program and supports potential Breakthrough Therapy designation pursuit. Watch for FDA meeting outcomes and Phase 3 initiation timeline. The small sample (n=4 for bleeding endpoint) limits statistical power but the effect size is compelling for a rare disease.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $114.24entry
- T+1 · 6mo ago −8.04%α −7.98% · $105.05
- T+5 · 6mo ago −0.22%α −1.18% · $113.99
- T+20 · 5mo ago +1.99%α −0.13% · $116.51
- T+60 · 3mo ago +35.07%α +30.55% · $154.30
Price Chart
How similar events traded
Executive Summary
Palvella presented positive Phase 2 TOIVA data at SID showing QTORIN rapamycin statistically significantly reduced bleeding in cutaneous venous malformation patients (100% of bleeding patients improved, mean +2.5 on cVM-IGA Bleeding, p=0.003). The data supports the drug's potential as the first FDA-approved therapy for this rare disease with >75,000 U.S. patients, but remains early-stage with no regulatory submission yet.
Key Facts
- 100% of patients with bleeding at baseline (n=4) showed improvement on cVM-IGA Bleeding at Week 12, with mean +2.5 point improvement (p=0.003)
- 100% of bleeding patients reported being 'satisfied' or 'very satisfied' with QTORIN rapamycin on TSQM at Week 12
- Phase 2 TOIVA is a single-arm, open-label, baseline-controlled trial; no comparator arm
- QTORIN rapamycin has potential to be first FDA-approved therapy for cutaneous venous malformations (>75,000 U.S. patients)
- Data presented at 83rd SID Annual Meeting; previously announced statistical significance on multiple endpoints in December 2025
Financial Impact
Early-stage biotech with $1.7B market cap; positive Phase 2 data supports pipeline value but no revenue yet. Addressable U.S. population >75,000 patients for a potential first-in-class therapy.
Risk Factors
- Phase 2 single-arm design with small sample size (n=4 for bleeding endpoint) limits generalizability
- No FDA-approved comparator; regulatory path uncertain for novel endpoint (cVM-IGA Bleeding)
- Clinical-stage biotech with no approved products; requires additional capital for Phase 3 and potential commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295760 |
Track record
36 reports on PVLA
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +32.31% at T+20 after the Jun 22, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
- Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
- Nov 5, 202611d ago Press Release Neutral 6/10 No price data
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers